Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sherlock Biosciences Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners. The prosecution is occurring across 2 distinct art units, which indicates that the company's filings are being reviewed by different specialized groups within the patent office.
The busiest examiner for this portfolio is HANEY, AMANDA MARIE, who is responsible for 1 pending office action. This 1 pending action is equal to the workload of the other of the 2 distinct examiners. Because the 2 pending office actions are split between 2 distinct examiners and 2 distinct art units, the company is engaging with different officials in different technical contexts.
Practitioners should note that the Biotechnology & Pharmaceuticals filings are being reviewed by 2 distinct examiners, providing different points of contact for the 2 pending office actions. The 2 distinct art units suggest a lack of concentration in a single technical group. HANEY, AMANDA MARIE manages 1 pending action, showing that no single examiner dominates the current portfolio. This distribution defines the current prosecution landscape for Sherlock Biosciences Inc.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292859 | IMPROVED CRISPR-CAS TECHNOLOGIES | HANEY, AMANDA MARIE | — |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292859 | IMPROVED CRISPR-CAS TECHNOLOGIES | HANEY, AMANDA MARIE | 1682 | §102§103DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | BAUSCH, SARAE L | 1699 | §102§112 | Non-Final OA | — | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSherlock Biosciences Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Amanda Marie Haney has the most, with 1 of Sherlock Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
